
Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target
Madrigal Pharmaceuticals (MDGL) Analyst Ratings
Bulls say
Madrigal Pharmaceuticals Inc. has reported robust growth for its medication, Rezdiffra, evidenced by a significant 44% quarter-over-quarter increase in the number of patients using the drug, resulting in a 33% quarter-over-quarter rise in net sales. Upcoming data from the Phase 2 MAESTRO-NAFLD study on compensated MASH cirrhosis is poised to enhance the prospects of the ongoing MAESTRO-Outcomes trial, thereby bolstering the validity of Rezdiffra in treating this serious condition. Furthermore, potential expansion into later-stage F4c could further widen the patient population, with supportive data anticipated from the Phase 3 MAESTRO-NAFLD-1 trial, signaling strong future growth opportunities for the company.
Bears say
Madrigal Pharmaceuticals faces a negative outlook primarily due to potential negative safety and efficacy results from late-stage clinical trials, which could lead to significant downward revisions in financial projections. Additionally, the company may encounter market access and reimbursement challenges that could hinder initial adoption of its product Rezdiffra, similar to issues experienced by other recent launches in related therapeutic areas. Furthermore, increasing competition in the field of metabolic dysfunction-associated steatohepatitis (MASH) could create long-term barriers to achieving a substantial market share for Madrigal's therapeutics.
This aggregate rating is based on analysts' research of Madrigal Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Madrigal Pharmaceuticals (MDGL) Analyst Forecast & Price Prediction
Start investing in Madrigal Pharmaceuticals (MDGL)
Order type
Buy in
Order amount
Est. shares
0 shares